STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANAB
  4. [Form 4] ANAPTYSBIO, INC Insider Trading Activity

AnaptysBio (NASDAQ: ANAB) CEO logs RSU vesting, tax sale and new option grant

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

AnaptysBio, Inc. reported insider equity activity by President and CEO Daniel Faga. On January 6, 2026, 17,850 restricted stock units (RSUs) were converted into the same number of shares of common stock for no cash consideration. On January 7, 2026, 9,202 shares of common stock were sold at $45.11 per share to cover tax withholding obligations related to RSU vesting, described as a non-discretionary “sell to cover” transaction.

Also on January 6, 2026, Faga received new equity awards consisting of 98,600 RSUs and a stock option for 133,400 shares with an exercise price of $43.91. The RSUs and option awards vest over several years, subject to continued service. After these transactions, Faga beneficially owned 466,787 shares of AnaptysBio common stock directly.

Positive

  • None.

Negative

  • None.
Insider Faga Daniel
Role President, CEO
Sold 9,202 shs ($415K)
Type Security Shares Price Value
Sale Common Stock 9,202 $45.11 $415K
Exercise Restricted Stock Unit 17,850 $0.00 --
Grant/Award Restricted Stock Unit 98,600 $0.00 --
Grant/Award Stock Option (right to buy) 133,400 $0.00 --
Exercise Common Stock 17,850 $0.00 --
Holdings After Transaction: Common Stock — 466,787 shares (Direct); Restricted Stock Unit — 17,850 shares (Direct); Stock Option (right to buy) — 133,400 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Faga Daniel
(Last) (First) (Middle)
C/O ANAPTYSBIO, INC.
10770 WATERIDGE CIRCLE, SUITE 210
(Street)
SAN DIEGO CA 92121
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President, CEO
3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/06/2026 M 17,850 A (1) 475,989 D
Common Stock 01/07/2026 S(2) 9,202 D $45.11 466,787 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 01/06/2026 M 17,850 (3) (3) Common Stock 17,850 $0 17,850 D
Restricted Stock Unit (1) 01/06/2026 A 98,600 (4) (4) Common Stock 98,600 $0 98,600 D
Stock Option (right to buy) $43.91 01/06/2026 A 133,400 (5) 01/05/2036 Common Stock 133,400 $0 133,400 D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
3. The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
4. The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
5. The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
/s/ Eric Loumeau, Attorney-in-Fact 01/08/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did ANAB President and CEO Daniel Faga report?

Daniel Faga reported RSU vesting into 17,850 shares of AnaptysBio common stock on January 6, 2026, a sale of 9,202 shares on January 7, 2026, and new grants of 98,600 RSUs plus a 133,400-share stock option.

Why did the ANAB CEO sell 9,202 shares of common stock?

The sale of 9,202 shares at $45.11 per share was to cover tax withholding obligations arising from the vesting and settlement of RSUs and is described as a non-discretionary “sell to cover” transaction.

How many AnaptysBio shares does the CEO beneficially own after these transactions?

Following the reported transactions, Daniel Faga beneficially owned 466,787 shares of AnaptysBio common stock directly.

What new RSU awards did AnaptysBio grant to its CEO?

On January 6, 2026, Daniel Faga received a new award of 98,600 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock for no consideration, vesting 25% annually starting January 6, 2027.

What are the terms of the new stock option granted to the ANAB CEO?

The stock option covers 133,400 shares of common stock with an exercise price of $43.91 per share. It vests 25% on January 6, 2027, then 1/48 of the total shares monthly until fully vested, subject to continued service.

How do the vested RSUs for the ANAB CEO work?

Each RSU represents a contingent right to receive 1 share of AnaptysBio common stock for no cash consideration upon settlement. One RSU grant vests 25% annually beginning January 6, 2024, and another vests 25% annually beginning January 6, 2027, in each case subject to continued service.

Is the ANAB CEO’s reported share sale considered discretionary trading?

The filing states that the 9,202-share sale was undertaken solely to satisfy tax withholding obligations through a “sell to cover” mechanism and does not represent a discretionary transaction by the reporting person.